Business
Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results
WIXOM, Mich., March 20, 2025--Rockwell Medical achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history.
About this update from Rockwell Medical, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/0257a7a2b1df026eedace13d6d0e096d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h6r2r.AhQuFqw0v11TJqJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0257a7a2b1df026eedace13d6d0e096d","width":400,"height":400}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history.","length":119,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023.","length":117,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023.","length":220,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":456,"olType":false},{"type":"text","content":"WIXOM, Mich., March 20, 2025--(BUSINESS WIRE)--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months and twelve months ended December 31, 2024.","length":377,"tagName":"p"},{"type":"text","content":""In 2024, we were successful in accomplishing our objectives to achieve profitability for the full-year on an adjusted EBITDA basis, generate over $100 million in net sales, and increase our gross margin," said Mark Strobeck, Ph.D., Rockwell Medical’s President and CEO. "While we expect 2025 to be a year of transition as we navigate changes within our customer base, we remain focused on sustained profitability for the full-year 2025 on an adjusted EBITDA basis. We plan to continue to identify additional business development opportunities to support our strategic objectives, diversify our product portfolio, and further optimize...